<unk>  (USAN, brand name Xermelo) is a prodrug of<unk> , which is an inhibitor of tryptophan hydroxylase. It is formulated as<unk>  etiprate — a hippurate salt of<unk> . On February 28, 2017, the U.S. Food and Drug Administration (FDA) approved<unk>  in combination with somatostatin analog (SSA) therapy for the treatment of adults with diarrhea associated with carcinoid syndrome that SSA therapy alone has inadequately controlled.<unk>  was approved for use in the European Union in September 2017. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Telotristat ethyl
Seviteronel
Ladostigil
Crofelemer
Tezacaftor
Lesinurad
Gestonorone caproate
Temgicoluril